Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Ac, adolescent, AgreementSM, antitumor, Assent, Atara, Authorisation, bioinert, Brexit, California, carryforward, CBR, CCPA, climate, clock, compassionate, conflict, contemplated, contrary, cyber, cyclophosphamide, denominated, destruction, detrimental, discharge, divergent, downturn, draft, drafted, dubbed, duty, EBMT, economy, enrichment, exit, fallback, FCA, feedback, fiduciary, fluid, furlough, Gamida, gamma, GDPR, geopolitical, German, hear, hearing, heterodimer, Iceland, illiquidity, indefinitely, Judgement, language, leaflet, Liechtenstein, likewise, linked, London, MA, microenvironment, modest, motion, Mustang, neurodegenerative, Nonemployee, Norway, notably, notification, older, Overnight, Paik, Parliament, PCT, people, pivotal, plaintiff, point, polyclonal, Poseida, postpone, practitioner, preempted, prolonged, radiopharmaceutical, reassessment, reengineered, referendum, regimen, registry, reinstated, rejected, reminding, revoked, rivogenlecleucel, Royal, Rudy, SAB, Seung, shareholder, shut, SOFR, somatic, SRC, steering, sterling, strain, stringent, sublease, suppressive, THRIVE, timeframe, titled, turnover, unclear, Union, unjust, unused, urge, veterinary, viewpoint, waste, weak, whichever, word
Removed:
addressable, arisen, Asia, bladder, BPCIA, BPX, capability, certainty, Composite, consultancy, Conversely, delivering, derive, dimmer, discontinuation, dose, Eastern, engraftment, epithelial, establishment, exclusively, forecast, fourth, frequent, graft, graph, half, inconsistent, injection, investigating, IXIC, Juno, Kite, Latin, mature, maximize, medium, metastatic, mitigating, NBI, neuroblastoma, onset, peer, Pfizer, preparing, preservation, prime, qualification, RAC, reactivity, reclassified, recombinant, redirect, reinvestment, renowned, reputable, showed, sickle, studying, susceptibility, tocilizumab, traded, Treasurer
Filing tables
Filing exhibits
Related press release
Associated BLCM transcripts
BLCM similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statements (Form S-3 Nos. 333-219020 and 333-226652) of Bellicum Pharmaceuticals, Inc., and |
(2) | Registration Statements (Form S-8 Nos. 333-201036, 333-216656, 333-218772, 333-220170, 333-223636 and 333-225554) pertaining to the 2006 Stock Option Plan, 2011 Stock Option Plan, 2014 Equity Incentive Plan, as amended, and 2014 Employee Stock Purchase Plan of Bellicum Pharmaceuticals, Inc. |
of our report dated March 12, 2019, with respect to the consolidated financial statements of Bellicum Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Bellicum Pharmaceuticals, Inc. for the year ended December 31, 2018.
/s/ Ernst & Young LLP
Houston, Texas
March 12, 2019